Paclitaxel in cancer therapy. Expert Opin. Pharmacother. 2002; 3 :755–766.Mekhail TM, and Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother. 2002; 3 :755–766.Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother. 2002; 3 :755–766. doi: 10.1517...
Nab-Paclitaxel: a bright new SPARC in taxane therapy of cancer Ackland SP,Bull JM,Boyle FM,et al.Nab-Paclitaxel:a brightnew SPARC in taxane therapy of cancer.Asia-Pacific J ClinOncol. 2009Ackland SP,Bull JM,Boyle FM,et al.Nab-Paclitaxel:a brightnew SPARC in taxane therapy of cancer. ...
While the combination of gemcitabine and nab-paclitaxel (Abraxane) has demonstrated survival benefits for patients with metastatic pancreatic cancer, oncologists are interested in knowing whether the regimen will transfer well into the adjuvant setting, according to experts who participated in an OncLive ...
Despite its clinical utility, cancer recurrence frequently occurs in patients due to the development of resistance to PTX. Resistance mechanisms in cancer cells treated with PTX include alterations in β-tubulin, the target molecule involved in mitosis, activation of molecular pathways enabling drug ...
Paclitaxel (PTXL) is used as adjuvant chemotherapy in patients with ovarian cancer since the 1990's. The author summarizes the first experiences with PTXL treatment and claims a high efficacy of the drug in mono as well as in combined chemotherapy. An overall response rate of 75%, a progres...
The topic of the current review is the nanoparticle albumin bound paclitaxel (nab-paclitaxel) development, which has opened a novel scenario in cancer treatment by the enhancement of paclitaxel delivery by the use of nanotechnology. 2. Taxane (First) Revolution of Cancer Therapy Taxanes are an imp...
PURPOSE: We assessed the safety and efficacy of paclitaxel administered by the logistically convenient 3-hour infusion to breast cancer patients who had disease progression within 12 months since prior therapy with anthracyclines. METHODS: Fifty-one patients with metastatic breast cancer who had all ...
The poor intracellular uptake and non-specific binding of anticancer drugs into cancer cells are the bottlenecks in cancer therapy. Nanocarrier platforms provide the opportunities to improve the drug efficacy. Here we show a carbon-based nanomaterial nan
Lipid carriers of hydrophobic paclitaxel (PTX) are used in clinical trials for cancer chemotherapy. Improving their loading capacity requires enhanced PTX solubilization. We compared the time-dependence of PTX membrane solubility as a function of PTX con
Thirteen patients were in the III(rd) stage and 16 patients in the IV(th) stage of the disease, 1 patient had a limited form and 1 an extended form of the disease. In the 1(st) line 11 patients with non- small cell lung cancer with the combination Taxol-Carboplatin (T-Carb) and ...